TP53 and neoplasm: The effect of TP53/RB1 mutation in ex20 ins/dup-positive tumors is uncertain, but the high incidence of co-existing mutations in tumor suppressors may contribute to chemoradiation resistance and poor prognosis of this subgroup of NSCLC.